This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kim, E.-J. Articles by Suh, K.-H. Search for Related Content PubMed PubMed Citation Articles by Kim, E.-J. Articles by Suh, K.-H. Social Bookmarking                   What's this?

Safety pharmacology of sibutramine mesylate, an anti-obesity drug

Korea Institute of Toxicology, KRICT, 100 Jang-Dong, Yuseong, Daejeon, South Korea ejkim{at}kitox.re.kr

Eun-Kyung Park

Korea Institute of Toxicology, KRICT, Yusong, Taejon, South Korea

Kwee-Hyun Suh

Hanmi Pharmaceutical Company, Ltd., Bundang, Kyeonggi-do, South Korea

Sibutramine mesylate is a new anti-obesity drug. It is a crystalline salt of sibutramine developed to improve the solubility of sibutramine hydrochloride. Methanesulfonic acid was used as a salt-forming acid instead of hydrochloric acid, resulting in a greatly improved solubility of 1000 mg/mL in water. Sibutramine mesylate was administered orally to ICR mice, Sprague ^/ respiratory system and the other organ systems. Following administration of sibutramine mesylate, spontaneous locomotor activity was significantly increased from 120 min to 24 hours at 3.45 mg/kg and from 30 min to 24 hours at 11.50 mg/kg. Furthermore, there were a decrease in hexobarbitalinduced sleep time, an increase in respiratory rate at 120 min, increases in intestinal transport capacity and gastric pH at 11.50 mg/kg, and decreases in gastric ^/ Dawley rats, and beagle dogs at dose levels of 1.15, 3.45, and 11.50 mg/kg to measure its effects on the central nervous system (CNS), general behaviour, cardiovascular volume and total acidity at 3.45 and 11.50 mg/kg. However sibutramine mesylate caused no effects on general behaviour, motor coordination, body temperature, analgesia, convulsion, blood pressure, heart rate, electrocardiogram, cardiac functions of the isolated rat heart, isolated smooth muscles and renal function. Based on the above results, it was concluded that sibutramine mesylate caused effects on the spontaneous locomotor activity, hexobarbital-induced sleep time, respiration, gastrointestinal transport, and gastric secretion at a dose level of 3.45 mg/kg or greater but caused no effects on other general pharmacological reactions.

Key Words: autonomic nervous system • cardiovascular-respira-tory system • central nervous system • general pharmacology • sibutramine mesylate

Human & Experimental Toxicology, Vol. 24, No. 3, 109-119 (2005)
DOI: 10.1191/0960327105ht510oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. Kim, S. Park, H. Lee, D. Kim, and E. Kim Electrophysiological safety of sibutramine HCl Human and Experimental Toxicology, July 1, 2008; 27(7): 553 - 558. [Abstract] [PDF]